JP2019508462A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508462A5 JP2019508462A5 JP2018548677A JP2018548677A JP2019508462A5 JP 2019508462 A5 JP2019508462 A5 JP 2019508462A5 JP 2018548677 A JP2018548677 A JP 2018548677A JP 2018548677 A JP2018548677 A JP 2018548677A JP 2019508462 A5 JP2019508462 A5 JP 2019508462A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydropyrrolo
- pyrazole
- carbonitrile
- phenyl
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 substituted Chemical class 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 208000008955 Mucolipidoses Diseases 0.000 claims 6
- 230000007812 deficiency Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- GGGOFAQLGFPVOQ-UHFFFAOYSA-N 3-phenyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound C1(=CC=CC=C1)C=1C2=C(NN=1)CN(C2)C#N GGGOFAQLGFPVOQ-UHFFFAOYSA-N 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 206010058892 Carnitine deficiency Diseases 0.000 claims 2
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims 2
- 208000032274 Encephalopathy Diseases 0.000 claims 2
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 claims 2
- 208000006136 Leigh Disease Diseases 0.000 claims 2
- 208000017507 Leigh syndrome Diseases 0.000 claims 2
- 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 claims 2
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims 2
- 206010072928 Mucolipidosis type II Diseases 0.000 claims 2
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims 2
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 208000006443 lactic acidosis Diseases 0.000 claims 2
- 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims 2
- 208000020468 mucolipidosis III alpha/beta Diseases 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 1
- JUVGEDHVBWLQLU-UHFFFAOYSA-N 1-(1-methylindazol-5-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CN1N=CC2=C1C=CC(=C2)N1N=CC2=C1CN(C2)C#N JUVGEDHVBWLQLU-UHFFFAOYSA-N 0.000 claims 1
- RGJYHIIRCTVIHI-UHFFFAOYSA-N 1-(1-phenylimidazol-4-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound N#CN1CC2=C(C1)N(N=C2)C1=CN(C=N1)C1=CC=CC=C1 RGJYHIIRCTVIHI-UHFFFAOYSA-N 0.000 claims 1
- BOYDSQYMTOVMAP-UHFFFAOYSA-N 1-(1-phenylpyrazol-4-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound N#CN1CC2=C(C1)N(N=C2)C1=CN(N=C1)C1=CC=CC=C1 BOYDSQYMTOVMAP-UHFFFAOYSA-N 0.000 claims 1
- XXGXMUVQOXAODU-UHFFFAOYSA-N 1-(1H-indazol-3-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound N#CN1CC2=C(C1)N(N=C2)C1=NNC2=C1C=CC=C2 XXGXMUVQOXAODU-UHFFFAOYSA-N 0.000 claims 1
- CMSCJJHUMGPEJA-UHFFFAOYSA-N 1-(2-fluorophenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound FC1=C(C=CC=C1)N1N=CC2=C1CN(C2)C#N CMSCJJHUMGPEJA-UHFFFAOYSA-N 0.000 claims 1
- XEGYLEDSQXPUSI-UHFFFAOYSA-N 1-(3-methoxyphenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound COC1=CC=CC(=C1)N1N=CC2=C1CN(C2)C#N XEGYLEDSQXPUSI-UHFFFAOYSA-N 0.000 claims 1
- JQACROPZTZISGG-UHFFFAOYSA-N 1-(4-fluorophenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound FC1=CC=C(C=C1)N1N=CC2=C1CN(C2)C#N JQACROPZTZISGG-UHFFFAOYSA-N 0.000 claims 1
- AHLCLDWMUIRZPK-UHFFFAOYSA-N 1-(4-methoxyphenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound COC1=CC=C(C=C1)N1N=CC2=C1CN(C2)C#N AHLCLDWMUIRZPK-UHFFFAOYSA-N 0.000 claims 1
- SCCOCFXSISOVJP-UHFFFAOYSA-N 1-(5-phenyl-1H-pyrazol-3-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound N#CN1CC2=C(C1)N(N=C2)C1=CC(=NN1)C1=CC=CC=C1 SCCOCFXSISOVJP-UHFFFAOYSA-N 0.000 claims 1
- YTUDTZUXRVSLDN-UHFFFAOYSA-N 1-benzyl-3-(2-methoxy-5-propan-2-ylphenyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound COC1=C(C=C(C=C1)C(C)C)C1=NN(CC2=CC=CC=C2)C2=C1CN(C2)C#N YTUDTZUXRVSLDN-UHFFFAOYSA-N 0.000 claims 1
- HGPLLHMZCCSMKO-UHFFFAOYSA-N 1-benzyl-3-(isoquinolin-3-ylamino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound N#CN1CC2=C(C1)C(NC1=CC3=CC=CC=C3C=N1)=NN2CC1=CC=CC=C1 HGPLLHMZCCSMKO-UHFFFAOYSA-N 0.000 claims 1
- LLVIBOLZPFHAQS-UHFFFAOYSA-N 1-methyl-3-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CN1N=C(C2=C1CN(C2)C#N)C1=CC=CC=C1 LLVIBOLZPFHAQS-UHFFFAOYSA-N 0.000 claims 1
- AINYECDWHLOUAS-UHFFFAOYSA-N 1-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound N#CN1CC2=C(C1)N(N=C2)C1=CC=CC=C1 AINYECDWHLOUAS-UHFFFAOYSA-N 0.000 claims 1
- PIZVMZGJPRKAKX-UHFFFAOYSA-N 1-quinolin-3-yl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound N#CN1CC2=C(C1)N(N=C2)C1=CC2=CC=CC=C2N=C1 PIZVMZGJPRKAKX-UHFFFAOYSA-N 0.000 claims 1
- YMJLEPMVGQBLHL-UHFFFAOYSA-N 1h-pyrazole-5-carbonitrile Chemical compound N#CC1=CC=NN1 YMJLEPMVGQBLHL-UHFFFAOYSA-N 0.000 claims 1
- PUWHDEMPPGOJPL-UHFFFAOYSA-N 2-methyl-3-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CN1N=C2C(=C1C1=CC=CC=C1)CN(C2)C#N PUWHDEMPPGOJPL-UHFFFAOYSA-N 0.000 claims 1
- SGYAYXGQLGJTSA-UHFFFAOYSA-N 3-(1-methylindazol-5-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CN1N=CC2=CC(=CC=C12)C=1C2=C(NN=1)CN(C2)C#N SGYAYXGQLGJTSA-UHFFFAOYSA-N 0.000 claims 1
- LBMJENCEMCJDAU-UHFFFAOYSA-N 3-(2-benzylpyrazol-3-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound C(C1=CC=CC=C1)N1N=CC=C1C=1C2=C(NN=1)CN(C2)C#N LBMJENCEMCJDAU-UHFFFAOYSA-N 0.000 claims 1
- PLGQXDOVJSLWPX-UHFFFAOYSA-N 3-(2-fluoro-5-methylphenyl)-1-methyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound FC1=C(C=C(C=C1)C)C=1C2=C(N(N=1)C)CN(C2)C#N PLGQXDOVJSLWPX-UHFFFAOYSA-N 0.000 claims 1
- SLLXJWBWPDBAFU-UHFFFAOYSA-N 3-(2-fluoro-5-methylphenyl)-2-methyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound FC1=C(C=C(C=C1)C)C1=C2C(=NN1C)CN(C2)C#N SLLXJWBWPDBAFU-UHFFFAOYSA-N 0.000 claims 1
- DVPNNNCKOSAVAJ-UHFFFAOYSA-N 3-(2-fluoro-5-methylphenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound FC1=C(C=C(C=C1)C)C=1C2=C(NN=1)CN(C2)C#N DVPNNNCKOSAVAJ-UHFFFAOYSA-N 0.000 claims 1
- YCDUBVATLLSRND-UHFFFAOYSA-N 3-(2-fluorophenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound FC1=C(C=CC=C1)C=1C2=C(NN=1)CN(C2)C#N YCDUBVATLLSRND-UHFFFAOYSA-N 0.000 claims 1
- CJNQBOBXYKJLOA-UHFFFAOYSA-N 3-(2-methoxy-4-pyrazol-1-ylphenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound COC1=C(C=CC(=C1)N1C=CC=N1)C1=C2CN(CC2=NN1)C#N CJNQBOBXYKJLOA-UHFFFAOYSA-N 0.000 claims 1
- PXHVHDOFIBAUCW-UHFFFAOYSA-N 3-(2-methoxy-5-propan-2-ylphenyl)-1-methyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound C(C)(C)C=1C=CC(=C(C=1)C=1C2=C(N(N=1)C)CN(C2)C#N)OC PXHVHDOFIBAUCW-UHFFFAOYSA-N 0.000 claims 1
- LNKWZICQKHVTSE-UHFFFAOYSA-N 3-(2-methoxy-5-propan-2-ylphenyl)-2-methyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound C(C)(C)C=1C=CC(=C(C=1)C1=C2C(=NN1C)CN(C2)C#N)OC LNKWZICQKHVTSE-UHFFFAOYSA-N 0.000 claims 1
- DDTMXFGNQVGMKO-UHFFFAOYSA-N 3-(2-methoxy-5-propan-2-ylphenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound COc1ccc(cc1-c1n[nH]c2CN(Cc12)C#N)C(C)C DDTMXFGNQVGMKO-UHFFFAOYSA-N 0.000 claims 1
- DLZBJZCDFSKSPS-UHFFFAOYSA-N 3-(2-methylpyrazol-3-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CN1N=CC=C1C=1C2=C(NN=1)CN(C2)C#N DLZBJZCDFSKSPS-UHFFFAOYSA-N 0.000 claims 1
- RHBUUHGQLBTRGB-UHFFFAOYSA-N 3-(3-cyanophenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound C(#N)C=1C=C(C=CC=1)C=1C2=C(NN=1)CN(C2)C#N RHBUUHGQLBTRGB-UHFFFAOYSA-N 0.000 claims 1
- IGDANYVMEOAYSL-UHFFFAOYSA-N 3-(3-fluorophenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound FC=1C=C(C=CC=1)C=1C2=C(NN=1)CN(C2)C#N IGDANYVMEOAYSL-UHFFFAOYSA-N 0.000 claims 1
- CHKVVIWIDQHQIH-UHFFFAOYSA-N 3-(4-chloro-2-methoxyphenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound COC1=C(C=CC(Cl)=C1)C1=C2CN(CC2=NN1)C#N CHKVVIWIDQHQIH-UHFFFAOYSA-N 0.000 claims 1
- ZMNKPCXOTOHCIV-UHFFFAOYSA-N 3-(4-cyanophenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound C(#N)C1=CC=C(C=C1)C=1C2=C(NN=1)CN(C2)C#N ZMNKPCXOTOHCIV-UHFFFAOYSA-N 0.000 claims 1
- XHEARYBLESEJLK-UHFFFAOYSA-N 3-(4-fluorophenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound FC1=CC=C(C=C1)C=1C2=C(NN=1)CN(C2)C#N XHEARYBLESEJLK-UHFFFAOYSA-N 0.000 claims 1
- RHLXYLPJJBCJEJ-UHFFFAOYSA-N 3-(4-morpholin-4-ylphenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound N#CN1Cc2[nH]nc(c2C1)-c1ccc(cc1)N1CCOCC1 RHLXYLPJJBCJEJ-UHFFFAOYSA-N 0.000 claims 1
- CRXAEZHYQKBIIL-UHFFFAOYSA-N 3-(4-phenoxyphenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound O(C1=CC=CC=C1)C1=CC=C(C=C1)C=1C2=C(NN=1)CN(C2)C#N CRXAEZHYQKBIIL-UHFFFAOYSA-N 0.000 claims 1
- JBGQYSLZJROGNG-UHFFFAOYSA-N 3-(4-phenylmethoxyphenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C=C1)C=1C2=C(NN=1)CN(C2)C#N JBGQYSLZJROGNG-UHFFFAOYSA-N 0.000 claims 1
- LEDICMICIXAOKQ-UHFFFAOYSA-N 3-(5-cyano-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-N,N-dimethylbenzenesulfonamide Chemical compound C(#N)N1CC=2NN=C(C=2C1)C=1C=C(C=CC=1)S(=O)(=O)N(C)C LEDICMICIXAOKQ-UHFFFAOYSA-N 0.000 claims 1
- LGHFYVPSZYNVEJ-UHFFFAOYSA-N 3-(5-cyano-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-N-cyclopropylbenzenesulfonamide Chemical compound C(#N)N1CC=2NN=C(C=2C1)C=1C=C(C=CC=1)S(=O)(=O)NC1CC1 LGHFYVPSZYNVEJ-UHFFFAOYSA-N 0.000 claims 1
- IVKKFIRXHPBEID-UHFFFAOYSA-N 3-(5-cyano-4,6-dihydropyrrolo[3,4-c]pyrazol-1-yl)-1H-pyrazole-5-carboxamide Chemical compound NC(=O)C1=NNC(=C1)N1N=CC2=C1CN(C2)C#N IVKKFIRXHPBEID-UHFFFAOYSA-N 0.000 claims 1
- XPXCVEUZLNMGDZ-UHFFFAOYSA-N 3-(5-cyano-4,6-dihydropyrrolo[3,4-c]pyrazol-1-yl)-N-(1-phenylethyl)benzamide Chemical compound CC(NC(=O)C1=CC(=CC=C1)N1N=CC2=C1CN(C2)C#N)C1=CC=CC=C1 XPXCVEUZLNMGDZ-UHFFFAOYSA-N 0.000 claims 1
- RUKUSKRNNYQAND-UHFFFAOYSA-N 3-(5-ethyl-2-methoxyphenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound C(C)C=1C=CC(=C(C=1)C=1C2=C(NN=1)CN(C2)C#N)OC RUKUSKRNNYQAND-UHFFFAOYSA-N 0.000 claims 1
- LYAPAMVUYLIWDO-UHFFFAOYSA-N 3-(5-fluoro-2-propan-2-yloxyphenyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound FC=1C=CC(=C(C=1)C=1C2=C(NN=1)CN(C2)C#N)OC(C)C LYAPAMVUYLIWDO-UHFFFAOYSA-N 0.000 claims 1
- JXFOYPPXSPQHIS-UHFFFAOYSA-N 3-(5-methyl-1H-indazol-4-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CC=1C(=C2C=NNC2=CC=1)C=1C2=C(NN=1)CN(C2)C#N JXFOYPPXSPQHIS-UHFFFAOYSA-N 0.000 claims 1
- WPYLYVHOWSRIDL-UHFFFAOYSA-N 3-(6-methoxypyridin-3-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound COC1=CC=C(C=N1)C=1C2=C(NN=1)CN(C2)C#N WPYLYVHOWSRIDL-UHFFFAOYSA-N 0.000 claims 1
- JJBMCXMUWLYSNP-UHFFFAOYSA-N 3-(6-propan-2-yloxypyridin-3-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound C(C)(C)OC1=CC=C(C=N1)C=1C2=C(NN=1)CN(C2)C#N JJBMCXMUWLYSNP-UHFFFAOYSA-N 0.000 claims 1
- VGCBGAOUNUBEBS-UHFFFAOYSA-N 3-(isoquinolin-3-ylamino)-2-methyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound C1=NC(=CC2=CC=CC=C12)NC1=C2C(=NN1C)CN(C2)C#N VGCBGAOUNUBEBS-UHFFFAOYSA-N 0.000 claims 1
- NGJBVKTXLFSMAK-UHFFFAOYSA-N 3-(isoquinolin-3-ylamino)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound C1=NC(=CC2=CC=CC=C12)NC=1C2=C(NN=1)CN(C2)C#N NGJBVKTXLFSMAK-UHFFFAOYSA-N 0.000 claims 1
- AZRBHYPOFXPIKN-UHFFFAOYSA-N 3-[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CN1CCC(CC1)N1N=CC(=C1)C=1C2=C(NN=1)CN(C2)C#N AZRBHYPOFXPIKN-UHFFFAOYSA-N 0.000 claims 1
- BUWVGYAPNOMAPP-UHFFFAOYSA-N 3-[2-chloro-5-(trifluoromethoxy)phenyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound ClC1=C(C=C(C=C1)OC(F)(F)F)C=1C2=C(NN=1)CN(C2)C#N BUWVGYAPNOMAPP-UHFFFAOYSA-N 0.000 claims 1
- OTMHRZKJSLANPT-UHFFFAOYSA-N 3-[2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound FC1=C(C=CC(=C1)N1CCN(CC1)C)C=1C2=C(NN=1)CN(C2)C#N OTMHRZKJSLANPT-UHFFFAOYSA-N 0.000 claims 1
- XVQNZZBWUWQBDF-UHFFFAOYSA-N 3-[2-fluoro-4-(trifluoromethyl)phenyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound FC1=C(C=CC(=C1)C(F)(F)F)C=1C2=C(NN=1)CN(C2)C#N XVQNZZBWUWQBDF-UHFFFAOYSA-N 0.000 claims 1
- UABKLFAPPJJCBC-UHFFFAOYSA-N 3-[3-(2-oxo-1,3-oxazolidin-3-yl)phenyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound O=C1OCCN1C=1C=C(C=CC=1)C=1C2=C(NN=1)CN(C2)C#N UABKLFAPPJJCBC-UHFFFAOYSA-N 0.000 claims 1
- BPJOBJXQTDRWAI-UHFFFAOYSA-N 3-[3-(2-oxopyrrolidin-1-yl)phenyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound O=C1N(CCC1)C=1C=C(C=CC=1)C=1C2=C(NN=1)CN(C2)C#N BPJOBJXQTDRWAI-UHFFFAOYSA-N 0.000 claims 1
- LEVLYGXWXBGJQO-UHFFFAOYSA-N 3-[3-(4-methylpiperazin-1-yl)phenyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CN1CCN(CC1)C=1C=C(C=CC=1)C=1C2=C(NN=1)CN(C2)C#N LEVLYGXWXBGJQO-UHFFFAOYSA-N 0.000 claims 1
- YWJQNWSVJMIZOQ-UHFFFAOYSA-N 3-[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CC=1C=C(C=CC=1N1CCN(CC1)C)C=1C2=C(NN=1)CN(C2)C#N YWJQNWSVJMIZOQ-UHFFFAOYSA-N 0.000 claims 1
- FOQDCUVFCWFVTF-UHFFFAOYSA-N 3-[4-(4-methylpiperazin-1-yl)phenyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C=1C2=C(NN=1)CN(C2)C#N FOQDCUVFCWFVTF-UHFFFAOYSA-N 0.000 claims 1
- HMBAMPKXRXDCEX-UHFFFAOYSA-N 3-[4-(4-methylpiperazine-1-carbonyl)phenyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CN1CCN(CC1)C(=O)C1=CC=C(C=C1)C=1C2=C(NN=1)CN(C2)C#N HMBAMPKXRXDCEX-UHFFFAOYSA-N 0.000 claims 1
- AUTMWVWUZFEKAJ-UHFFFAOYSA-N 3-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CN1CCN(CC1)C1=CC=C(C=N1)C=1C2=C(NN=1)CN(C2)C#N AUTMWVWUZFEKAJ-UHFFFAOYSA-N 0.000 claims 1
- XDTKXJNVUDTRAP-UHFFFAOYSA-N 3-methyl-1-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CC=1C2=C(N(N=1)C1=CC=CC=C1)CN(C2)C#N XDTKXJNVUDTRAP-UHFFFAOYSA-N 0.000 claims 1
- GHUWLPWYLALVPP-UHFFFAOYSA-N 3-phenyl-1-propan-2-yl-4,6-dihydropyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical compound CC(C)N1N=C(C2=C1CN(C2)C#N)C1=CC=CC=C1 GHUWLPWYLALVPP-UHFFFAOYSA-N 0.000 claims 1
- GSUYMAWSAXNDFL-UHFFFAOYSA-N 4-(5-cyano-3-methyl-4,6-dihydropyrrolo[3,4-c]pyrazol-1-yl)benzamide Chemical compound CC1=NN(C2=C1CN(C2)C#N)C1=CC=C(C=C1)C(N)=O GSUYMAWSAXNDFL-UHFFFAOYSA-N 0.000 claims 1
- TZUQFYVDFKTPSC-UHFFFAOYSA-N 4-(5-cyano-4,6-dihydropyrrolo[3,4-c]pyrazol-1-yl)-N-methylbenzamide Chemical compound CNC(=O)C1=CC=C(C=C1)N1N=CC2=C1CN(C2)C#N TZUQFYVDFKTPSC-UHFFFAOYSA-N 0.000 claims 1
- ANDMKJADAOYYNM-UHFFFAOYSA-N 4-(5-cyano-4,6-dihydropyrrolo[3,4-c]pyrazol-1-yl)benzamide Chemical compound NC(=O)C1=CC=C(C=C1)N1N=CC2=C1CN(C2)C#N ANDMKJADAOYYNM-UHFFFAOYSA-N 0.000 claims 1
- XNJCOKWUWSPVJP-UHFFFAOYSA-N 4-[5-cyano-3-(pyridin-2-ylamino)-4,6-dihydropyrrolo[3,4-c]pyrazol-1-yl]benzamide Chemical compound NC(=O)C1=CC=C(C=C1)N1N=C(NC2=NC=CC=C2)C2=C1CN(C2)C#N XNJCOKWUWSPVJP-UHFFFAOYSA-N 0.000 claims 1
- ZBLHTONLHMDQPV-UHFFFAOYSA-N 4H-pyrazole-3-carbonitrile Chemical compound N#CC1=NN=CC1 ZBLHTONLHMDQPV-UHFFFAOYSA-N 0.000 claims 1
- QFLFGSAXJXYOLC-UHFFFAOYSA-N 5-(5-cyano-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-N-methylpyridine-2-carboxamide Chemical compound C(#N)N1CC=2NN=C(C=2C1)C=1C=CC(=NC=1)C(=O)NC QFLFGSAXJXYOLC-UHFFFAOYSA-N 0.000 claims 1
- BLXCZNGLZTVFMT-UHFFFAOYSA-N 5-(5-cyano-4,6-dihydropyrrolo[3,4-c]pyrazol-1-yl)-2-methoxy-N-methylbenzamide Chemical compound CNC(=O)C1=C(OC)C=CC(=C1)N1N=CC2=C1CN(C2)C#N BLXCZNGLZTVFMT-UHFFFAOYSA-N 0.000 claims 1
- PEUFOYZYJDYRES-UHFFFAOYSA-N 6-chloro-N-[(5-cyano-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)methyl]imidazo[1,2-a]pyridine-2-carboxamide Chemical compound ClC=1C=CC=2N(C=1)C=C(N=2)C(=O)NCC=1C2=C(NN=1)CN(C2)C#N PEUFOYZYJDYRES-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 claims 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 201000005943 Barth syndrome Diseases 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 101150072353 CAPN3 gene Proteins 0.000 claims 1
- 102100032539 Calpain-3 Human genes 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000021075 Creatine deficiency syndrome Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 1
- 102000015782 Electron Transport Complex III Human genes 0.000 claims 1
- 108010024882 Electron Transport Complex III Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 101710150008 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000035155 Mitochondrial DNA-associated Leigh syndrome Diseases 0.000 claims 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 claims 1
- QUCDPFLAOIUHNT-UHFFFAOYSA-N N-[(5-cyano-1-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazol-3-yl)methyl]-4-methylbenzamide Chemical compound CC1=CC=C(C=C1)C(=O)NCC1=NN(C2=C1CN(C2)C#N)C1=CC=CC=C1 QUCDPFLAOIUHNT-UHFFFAOYSA-N 0.000 claims 1
- WZXAYLRPRHLARB-UHFFFAOYSA-N N-[(5-cyano-1-phenyl-4,6-dihydropyrrolo[3,4-c]pyrazol-3-yl)methyl]acetamide Chemical compound C(#N)N1CC=2N(N=C(C=2C1)CNC(C)=O)C1=CC=CC=C1 WZXAYLRPRHLARB-UHFFFAOYSA-N 0.000 claims 1
- ZXMIBFUXEIZJLA-UHFFFAOYSA-N N-[(5-cyano-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)methyl]-3-phenyl-1H-pyrazole-5-carboxamide Chemical compound O=C(NCC1=NNC2=C1CN(C2)C#N)C1=CC(=NN1)C1=CC=CC=C1 ZXMIBFUXEIZJLA-UHFFFAOYSA-N 0.000 claims 1
- OZFDTTDOEOOFNC-UHFFFAOYSA-N N-[3-(5-cyano-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenyl]cyclopropanesulfonamide Chemical compound C(#N)N1CC=2NN=C(C=2C1)C=1C=C(C=CC=1)NS(=O)(=O)C1CC1 OZFDTTDOEOOFNC-UHFFFAOYSA-N 0.000 claims 1
- MDJJLLAPNCTYIR-UHFFFAOYSA-N N-[3-(5-cyano-4,6-dihydropyrrolo[3,4-c]pyrazol-1-yl)phenyl]cyclopropanesulfonamide Chemical compound C(#N)N1CC=2N(N=CC=2C1)C=1C=C(C=CC=1)NS(=O)(=O)C1CC1 MDJJLLAPNCTYIR-UHFFFAOYSA-N 0.000 claims 1
- JIBUNAOLKHGJCY-UHFFFAOYSA-N N-benzyl-4-(5-cyano-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzamide Chemical compound C(C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C=1C2=C(NN=1)CN(C2)C#N)F)=O JIBUNAOLKHGJCY-UHFFFAOYSA-N 0.000 claims 1
- YPBWYBGTYZHFQL-UHFFFAOYSA-N N-benzyl-4-(5-cyano-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)benzamide Chemical compound C(C1=CC=CC=C1)NC(C1=CC=C(C=C1)C=1C2=C(NN=1)CN(C2)C#N)=O YPBWYBGTYZHFQL-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010029333 Neurosis Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical class 0.000 claims 1
- 125000000304 alkynyl group Chemical class 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- UCOHKZKRNWNULS-UHFFFAOYSA-N aminocyanamide Chemical group NNC#N UCOHKZKRNWNULS-UHFFFAOYSA-N 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 201000008609 cerebral creatine deficiency syndrome Diseases 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000003531 maternally-inherited Leigh syndrome Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 claims 1
- 230000004065 mitochondrial dysfunction Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- DTPSXFMGMQOVTG-UHFFFAOYSA-N n-[4-[3-(2-aminocyclopropyl)phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide Chemical compound NC1CC1C1=CC=CC(OCCC(NC(=O)C=2C=CC=CC=2)C(=O)NCC=2C=CC=CC=2)=C1 DTPSXFMGMQOVTG-UHFFFAOYSA-N 0.000 claims 1
- 101150022123 ncl-1 gene Proteins 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1604638.5 | 2016-03-18 | ||
| GBGB1604638.5A GB201604638D0 (en) | 2016-03-18 | 2016-03-18 | Novel compounds |
| PCT/GB2017/050755 WO2017158381A1 (en) | 2016-03-18 | 2017-03-17 | 4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1h)-carbonitrile derivates for trating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019508462A JP2019508462A (ja) | 2019-03-28 |
| JP2019508462A5 true JP2019508462A5 (enExample) | 2020-03-05 |
| JP6959248B2 JP6959248B2 (ja) | 2021-11-02 |
Family
ID=55968542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548677A Active JP6959248B2 (ja) | 2016-03-18 | 2017-03-17 | 癌治療用の４，６−ジヒドロピロロ［３，４−ｃ］ピラゾール−５（１Ｈ）−カルボニトリル誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11306096B2 (enExample) |
| EP (1) | EP3430012B1 (enExample) |
| JP (1) | JP6959248B2 (enExample) |
| CN (1) | CN108473502B (enExample) |
| GB (1) | GB201604638D0 (enExample) |
| MA (1) | MA43745A (enExample) |
| WO (1) | WO2017158381A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3277677T (lt) | 2015-03-30 | 2021-05-25 | Mission Therapeutics Limited | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
| EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| MA43753A (fr) | 2016-03-24 | 2018-11-28 | Mission Therapeutics Ltd | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) * | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| JP7208931B2 (ja) | 2017-06-20 | 2023-01-19 | ミッション セラピューティクス リミティド | Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類 |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| JP7349450B2 (ja) | 2018-04-25 | 2023-09-22 | バイエル・アクチエンゲゼルシヤフト | 殺有害生物剤としての新規ヘテロアリール－トリアゾール化合物及びヘテロアリール－テトラゾール化合物 |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| EP3837262B1 (en) | 2018-08-14 | 2026-06-17 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| EP4218934B1 (en) | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| WO2021155264A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155262A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| MX2022012578A (es) | 2020-04-08 | 2022-11-07 | Mission Therapeutics Ltd | N-cianopirrolidinas con actividad como inhibidores de usp30. |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| KR20230016674A (ko) | 2020-05-28 | 2023-02-02 | 미션 테라퓨틱스 엘티디 | 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체 |
| WO2021245186A1 (en) | 2020-06-04 | 2021-12-09 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| RS67140B1 (sr) | 2020-06-08 | 2025-09-30 | Mission Therapeutics Ltd | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| GB202200753D0 (en) | 2022-01-21 | 2022-03-09 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
| GB202500610D0 (en) | 2025-01-16 | 2025-03-05 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003530384A (ja) | 2000-04-06 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | カテプシンシステインプロテアーゼ阻害薬 |
| WO2011087740A1 (en) | 2009-12-22 | 2011-07-21 | Schering Corporation | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| JP5852658B2 (ja) * | 2010-09-24 | 2016-02-03 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | デユビキチナーゼ阻害剤およびその使用方法 |
| EP2721029B1 (en) | 2011-06-16 | 2018-07-18 | Merck Sharp & Dohme Corp. | Imidazopyridin-2-one derivatives |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| JP5833764B2 (ja) * | 2011-09-30 | 2015-12-16 | 山東軒竹医薬科技有限公司 | 縮合環を有するオキサゾリドン（ｏｘａｚｏｌｉｄｏｎｅ）類の抗菌物質 |
| EP2938610A2 (en) * | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| MX358346B (es) | 2014-04-04 | 2018-08-15 | Syros Pharmaceuticals Inc | Inhibidores de la quinasa dependiente de ciclina 7 (cdk7). |
| CN111393434B (zh) * | 2014-04-30 | 2022-11-04 | 哥伦比亚大学董事会 | 取代的4-苯基哌啶及其制备和用途 |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| LT3277677T (lt) * | 2015-03-30 | 2021-05-25 | Mission Therapeutics Limited | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
| EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| MA43753A (fr) | 2016-03-24 | 2018-11-28 | Mission Therapeutics Ltd | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
-
2016
- 2016-03-18 GB GBGB1604638.5A patent/GB201604638D0/en not_active Ceased
-
2017
- 2017-03-17 CN CN201780007893.4A patent/CN108473502B/zh active Active
- 2017-03-17 EP EP17713402.0A patent/EP3430012B1/en active Active
- 2017-03-17 WO PCT/GB2017/050755 patent/WO2017158381A1/en not_active Ceased
- 2017-03-17 MA MA043745A patent/MA43745A/fr unknown
- 2017-03-17 JP JP2018548677A patent/JP6959248B2/ja active Active
- 2017-03-17 US US16/080,229 patent/US11306096B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7216682B2 (ja) | Ｕｓｐ３０阻害剤としての１－シアノ－ピロリジン化合物 | |
| CN108473502B (zh) | 用于治疗癌症的4,6二氢吡咯并[3,4-c]吡唑-5(1h)-腈衍生物 | |
| JP6081582B2 (ja) | Ｗｎｔシグナリング阻害剤、組成物およびその用途としての化合物 | |
| CN108368089B (zh) | 一种去泛素化酶抑制剂 | |
| CA2594477C (en) | Pharmaceutical compounds | |
| JP2019504009A5 (enExample) | ||
| CN101146532B (zh) | 药物化合物 | |
| US10285988B2 (en) | Compounds for treatment of fibrosis diseases | |
| JP2018510183A5 (enExample) | ||
| JP2022546717A (ja) | Ｕｓｐ３０阻害剤としての活性を有する置換シアノピロリジン類 | |
| JP2019533659A5 (enExample) | ||
| CN109790112A (zh) | 具有作为usp30抑制剂活性的氰基吡咯烷衍生物 | |
| JP2018524367A5 (enExample) | ||
| MX2007008809A (es) | Combinaciones de inhibidores de pirazol cinasa y otros agentes antitumor. | |
| JP2017532360A5 (enExample) | ||
| AU2015402778B2 (en) | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | |
| KR20110031372A (ko) | 피리디노-피리디논 유도체, 그의 제조, 및 그의 치료적 용도 | |
| TW202313050A (zh) | 組合療法 | |
| ES2978337T3 (es) | Combinación de regonafenib y nivolumab para el tratamiento contra el cáncer | |
| CN107074814A (zh) | 葡萄糖转运抑制剂 | |
| JP2023528310A5 (enExample) | ||
| JP2017095498A (ja) | Ｗｎｔシグナリング阻害剤、組成物およびその用途としての化合物 |